Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07443306 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Intermediate to High Risk Myelofibrosis

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study title revisedv5
  2. Re-verified, no change to tracked fieldsv4
  3. Recruitment opened
    • Study sites: 0 to 2
    • Start date: Apr 30, 2026 to Mar 18, 2026
    v3
  4. Interventions: Flonoltinib 50mg (Drug), Flonoltinib 75mg (Drug) to Flonoltinib Maleate (Drug)
    • Study title shortened, about 12 words
    • Study arms: 2 to 1
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial adopts a single arm, open label, multi center clinical trial design, with a planned enrollment of approximately 64 participants in the intermediate to high risk MF trial who are refractory, relapsed, or intolerant to JAK inhibitor . Select successful trial participants and allocate flonoltinib maleate tablets based on platelet count levels during the screening period, qd,Oral administration on an empty stomach until the participants meet the withdrawal criteria.
Trial Details
NCT Number NCT07443306
Lead Sponsor Chengdu Zenitar Biomedical Technology Co., Ltd
Conditions
(from sponsor)		 MF
Enrollment 64 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov